OFEV® (Nintedanib)

- signifikante Reduktion...
  - der jährlichen Abnahme der Lungenfunktion (-49%)\(^1,2\)
  - des Risikos adjudizierter*, akuter Exazerbationen (-68%)\(^1,2\)
  - des Risikos der on-treatment Mortalität (-43%)\(^3\)

(Gepoolte Daten aus 3 Studien (HR 0.57 [95% CI: 0.34, 0.97]; p=0.0274)

- einfache Einnahme, 1 Kapsel 2x täglich\(^1,2\)

Referenzen
1. Fachinformation OFEV® unter www.swissmedic.ch oder www.swissmedicinfo.ch
DOI: 10.1055/s-0035-1544831

* Bewertung durch ein unabhängiges Expertengremium

OFEV®: Nintedanibbesilat (Tyrosinkinaseinhibitor). \(\Delta\) Behandlung der idiopathischen Lungenfibrose (IPF) und Verlangsamung des Fortschreitens der Erkrankung.

International Journal of Thoracic Medicine


Editor-in-Chief

F.J.F. Herth, Heidelberg

Associate Editors

K.E. Bloch, Zurich
A. Boehler, Zurich
D.E. Bouros, Athens
A. Chetta, Parma
V. Cottin, Lyon
C. Dooms, Leuven
E. Eber, Graz
S. Gasparini, Ancona
J. Hammer, Basel
C.F. Koegelenberg, Cape Town
C. Lange, Borstel
M. Lommatzsch, Rostock
M. Miravitlles, Barcelona
J. Müller-Quernheim, Freiburg
L.P. Nicod, Lausanne
D. Olivieri, Parma
W. Randerath, Solingen
P.L. Shah, London
S. Siddiqui, Leicester
D.-J. Siebos, Groningen
O.S. Usmani, London
S. van Eeden, Vancouver, B.C.
K. Yasufuku, Toronto, Ont.

Editorial Board

P.J. Barnes, London
X. Basagana Flores, Barcelona
S. Bilaceroglu, Izmir
E. Brambilla, Grenoble
P. Camus, Dijon
M. Cazzola, Rome
P.N. Chhajed, Mumbai
U. Costabel, Essen
H. Dutau, Marseille
S. Fernandez-Bussy, Santiago de Chile
A. Foresi, Sesto San Giovanni
M.E. Froudarakis, Alexandroupolis
G. Hoheisel, Leipzig
M. Humbert, Clamart
G. Izbicki, Jerusalem
M. Kneussl, Vienna
M. Kreuter, Heidelberg
N. Künzli, Basel
S. Li, Guangzhou
W. Li, Chengdu
P.N. Mathur, Indianapolis, Ind.
A.R.L. Medford, Bristol
A. Melha, Boston, Mass.
T. Nakajima, Chiba
V. Poletti, Forli
H.-B. Ris, Lausanne
F. Rodriguez-Panadero, Sevilla
I. Rubinstein, Chicago, Ill.
T. Schaberg, Rotenburg
M. Solé, Basel
S. Spiro, London
A. Valipour, Vienna
A. Warth, Heidelberg
H. Wirtz, Leipzig
E.F.M. Wouters, Maastricht

KARGER

Printed in Switzerland on acid-free and non-aging paper
(ISO 9706) by Werner Druck & Medien AG, Basel
Submission
Manuscripts written in English should be submitted using the online submission website at:
www.karger.com/res
Should you experience any problems with your submission, please contact
res@karger.com
S. KARGER AG
Editorial Office “Respiration”
PO Box
CH–4009 Basel (Switzerland)
All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Conditions
All manuscripts are subject to an editorial process involving the Editor-in-Chief, an Associate Editor and reviewers. Notification can be expected within two months from the date of receipt. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Respiration and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Clinical Trials: In accordance with the recommendations of the International Committee of Medical Journal Editors, the journal requires that all clinical trials having commenced on or after 1 July 2005 be registered in a public trial registry accessible free of charge. Please consult http://www.icmje.org/index.html#clin_trials for further details. Respiration has implemented the expanded definition stating that “any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes”. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and processes-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

The journal consists of the following sections:
1. Thematic Review Series
2. Editorial Comments
3. Clinical Investigations
4. Interventional Pulmonology
5. Basic Science Investigations
6. The Eye Catcher
7. Novel Insights from Clinical Practice
8. What Is Your Diagnosis?
9. Reviews
10. Guidelines
11. Clinico-Pathological Conferences
12. Letters to the Editor

Reviews: Invited reviews, if accepted, are not subject to page charges. Unsolicited reviews may also be submitted for consideration.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in respiratory medicine are also welcome. Letters to the Editor should be no longer than one printed page.

Eye Catchers: Maximum 1 printed page. Text may not exceed 250 words to allow sufficient space for pictorial material, which is the main object of an Eye Catcher. Maximum 2 references and 2–5 keywords.

Novel Insights from Clinical Practice (formerly Case Reports):
Maximum 7 authors. The publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. Highlighted boxes containing one or two bullet points on “Established facts” (what is already known) and “Novel insights” (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation. The text per box should be limited to 1–2 very short sentences. The manuscript should be presented with an abstract (unstructured, max. 200 words), followed by introduction, case report and discussion. Maximum 3 figures.

What Is Your Diagnosis?: Select catchy title not disclosing the diagnosis. Page 1: Case report and 1–2 illustrations and figures. Page 2: “What is the diagnosis?” Page 3: “What is the diagnosis?” Page 4: The diagnosis followed by a short description of what diagnostic procedures were done to reach the diagnosis and the discussion with references. Maximum 15 references and include 3–5 key words.

Guidelines: Consensus Guidelines are welcome from working groups to provide guidance in key and emerging areas in all fields of respiratory medicine. Such guidelines are also subject to a reviewing process.

Patient Consent: This is required for ALL articles containing personal information about the patient submitted for publication in the following sections:
Novel Insights from Clinical Practice
What Is Your Diagnosis?
Eye Catcher

Signed patient consent must be obtained from the patient, guardian or next of kin (or a statement that the patient was not alive at the time of writing) and submitted along with the manuscript. For Patient Consent Form see www.karger.com/res/Guidelines

Arrangement
Pages should be numbered throughout the manuscript text. Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head. Full address: The exact postal address of the corresponding author complete with postal code must be given at the foot of the appropriate page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 250 words. Abstracts of papers submitted for publication in the sections Clinical Investigations, Basic Science Investigations, Interventional Pulmonology, and Technical Notes should be structured as follows:
Background: What is the major motive that prompted the study?
Objectives: What is the purpose of the study?
Methods: How was the study done?
Results: Most important findings.
Conclusions: Most important conclusions.

Introduction
What is the main question? State your considerations leading to the formulation of this question.

Material and Methods
Prior approval of an Institutional Review Board (IRB) is required for all investigations involving human subjects and animals. Animal experimentation must be performed according to the Helsinki Declaration.

Study design: Provide a short survey of the tests or experiments. Include the independent variable(s) manipulated, the dependent variable(s) measured and all controls.

Methods: Describe methods and apparatus in detail. Provide references and brief description of methods already published. Identify drugs and chemicals, including generic name, dosage and administration. Describe the pre-study condition of patients or animals.

Analysis: Define the variables. Use statistical analysis that is appropriate for the study. Describe statistical methods used for each analysis; provide references for tests that are not well known.

Results
A concise report of important results only. Use figures and tables for the presentation of data; summarize the most important observations in the text. Start and end dates of the study must be indicated (from ... to ... preferably exact dates, but at least months and year[s]).

Discussion
Summarize main results and make sure you can answer the question asked in the introduction, briefly supporting the answer with the relevant results. Explain and defend the answer, comment on contradictory or unexpected results and discrepancies with previous findings. Elaborate on new and important aspects of the study.

Acknowledgements
Use this section to name persons who have contributed to the article, but whose contributions do not justify authorship.

Footnotes
Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and Illustrations
Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger.com/res/).

Color illustrations
Online Edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.
References
In the text identify references by Arabic numerals (in square brackets). Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theocharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

SI Units
Since the United States of America and other countries outside Europe where Respiration is read have not accepted the SI system, authors using SI units should add the conventional units in parentheses, for example: pO2 = 10 kPa (75 mm Hg).

Digital Object Identifier (DOI)
Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 Mb in size.

Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://www.karger.com/doi. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Page Charges
There are no page charges for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at a cost of CHF 325.00. The allotted size of a paper is equal to approx. 12 manuscript pages (including tables, illustrations and references).

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchState or Mendelejo) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:
• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement: “This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi/[insert DOI number].”

It is the author’s responsibility to fulfill these requirements. For papers published online first with a DOI number only, full citations details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Manuscripts to be archived in PubMed Central due to funding requirements will be submitted by Karger on the author’s behalf (see Funding Organizations (NIH etc.)). For self-archiving Author’s ChoiceTM (Gold Open Access) articles, see Author’s Choice138.

Author’s ChoiceTM
Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

The final, published version of the article may be posted at any time and in any repository or on other websites, in accordance with the relevant Creative Commons license. Reposted Open Access articles must:
• Follow the terms of the relevant Creative Commons license
• Be linked to the final version on www.karger.com

Include the following statement: “The final, published version of this article is available at http://www.karger.com/doi/[insert DOI number].”

It is the author’s responsibility to fulfill these requirements. For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their Open Access through Author’s Choice138, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

E-publication First
All articles are published electronically ahead of print with a DOI number and are supplemented later with the definitive reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Financial Disclosure and Conflicts of Interest
Authors must disclose any and all financial involvement in any organization with a direct financial interest in the subject discussed in the submitted manuscript. Any conflict of interest for a given manuscript must be dealt with according to the statement of the International Committee of Medical Journal Editors (the "Vancouver Group") (Lancet 1993;341:742).

Further Information
For any further details please contact the Editorial Department "Respiration", Fax +41 61 306 14 34.
Contents

See the journal website for contents
Focusing on the special needs of AYA cancer patients

Tumors in Adolescents and Young Adults

Editors
Daniel P. Stark
Gilles Vassal

The field of adolescents and young adults (AYA) oncology is experiencing a very challenging time. This book is a guide to the key issues for any clinician and health professional managing AYA with cancer in Europe. Emphasis is on collaboration between adult and pediatric specialists. Authors present their perception of the current state of the most prominent primary issues in AYA oncology.

Chapters cover cross-cutting issues such as disease epidemiology, systems of care, access to innovative therapy and late effects of treatment and survivorship for AYA-onset cancers. There are discussions of the latest developments and the most important cancer types in AYA, including the shared perspectives of adult and pediatric specialists. Throughout the book recurrent challenges to the AYA community are exposed and solutions proposed.

Tumors in Adolescents and Young Adults is highly recommended to any oncologist or hematologist treating patients aged 15 to 39 diagnosed with cancer. It will also be of interest to other members of the multidisciplinary teams involved with this patient group.

Contents
Preface: Stark, D.P.; Vassal, G.

Cross-Cutting Issues
- Epidemiology of Adolescents and Young Adults with Cancer in Europe: Desandes, E.; Stark, D.P.
- Supportive Care: Olsen, P.R.; Lorenzo, R.
- Long-Term Follow-Up and Survivorship: Tsirou, A.; Hjorth, L.
- Increasing Access to Clinical Trials and Innovative Therapy for Teenagers and Young Adults with Cancer – A Multiple Stakeholders and Multiple Steps Process: Gaspar, N.; Fern, L.
- Collaboration and Networking: Husson, O.; Manten-Horst, E.; van der Graaf, W.T.A.

Specific Illnesses
- Adult Cancers in Adolescents and Young Adults: Laurence, V.; Marples, M.; Stark, D.P.
- Pediatric Cancers and Brain Tumors in Adolescents and Young Adults: McCabe, M.G.; Valteau-Couanet, D.
- Leukemia: Juliusson, G.; Hough, R.
- Lymphoma in Adolescents and Young Adults: Brugères, L.; Brice, P.
- Germ Cell Tumors in Adolescents and Young Adults: Calaminus, G.; Joffe, J.
- Sarcomas of Soft Tissue and Bone: Ferrari, A.; Dirksen, U.; Bielack, S.

Author Index
Subject Index

The easiest way to order: www.karger.com/pritr

KARGER
The Journal of Innate Immunity is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications, reviews, commentaries and letters to the editors. In addition to regular papers, some issues feature a special section with a thematic focus.

Selected contributions
- Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity: Kleinijenhuis, J.; Quintin, J.; Preijers, F. (Nijmegen); Benn, C.S. (Copenhagen); Joosten, L.A.B.; Jacobs, C.; van Loenhout, J. (Nijmegen); Xavier, R.J. (Boston, Mass./Cambridge, Mass.); Aaby, P. (Copenhagen); van der Meer, J.W.M.; van Crevel, R.; Netea, M.G. (Nijmegen)
- M1 and M2 Macrophages: The Chicken and the Egg of Immunity: Mills, C.D. (Marine on St. Croix, Minn.); Ley, K. (La Jolla, Calif.)
- Inside-Out Signaling Pathways from Nuclear Reactive Oxygen Species Control Pulmonary Innate Immunity: Choudhary, S.; Boldogh, I. (Galveston, Tex.)
- Elie Metchnikoff, the Man and the Myth: Gordon, S. (Oxford)
- Some Important Milestones in the Field of Blood Clotting: Doolittle, R.F. (La Jolla, Calif.)
- Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity: Dai, J.; El Gazzar, M.; Li, G.Y.; Moorman, J.P.; Yao, Z.Q. (Johnson City, Tenn.)
- C4a: An Anaphylatoxin in Name Only: Barnum, S.R. (Birmingham, Ala.)
Wenn Ihr COPD-Patient* mehr braucht

SPIOLTO® RESPMAT®
1× täglich (2 Sprühstösse)1

mehr Atemvolumen2
mehr Lebensqualität4
mehr Wirksamkeit1–4
mehr Leichtigkeit beim Inhalieren5–7

* Bronchienerweiternde Erhaltungstherapie bei COPD-Patienten, bei welchen ein tief dosierter LAMA oder LABA allein nicht genügend ist.


301 Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study
Boeselt, T.; Nell, C.; Lütteken, L.; Kehr, K.; Koepke, J.; Apelt, S.; Veith, M.; Beutel, B. (Marburg); Spielmanns, M. (Leverkusen Opladen/Witten); Greulich, T.; Vogelmeier, C.F.; Kenn, K. (Marburg); Janciauskiene, S. (Hannover); Ailler, P.; Koczuulla, A.R. (Marburg)

311 Blood Pressure Variability in Obstructive Sleep Apnoea: Data from 4 Randomised Controlled CPAP Withdrawal Trials
Lettau, F.; Schwarz, E.I. (Zurich); Stradling, J.R. (Oxford); Kohler, M. (Zurich)

319 A Comparison of Different Training Methods in the Successful Learning of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Zhang, W.C. (Shanghai); Chen, W. (Shanghai/Baltimore, MD); Zhou, J.P. (Shanghai); Lerner, A.D. (Baltimore, MD); Ni, L.; Shen, J.M.; Yan, T.L.; Zhou, M.; Shi, G.C. (Shanghai); Xiang, Y. (Shanghai/Baltimore, MD)

327 Endobronchial Ultrasound Elastography for Evaluation of Intrathoracic Lymph Nodes: A Pilot Study
Sun, J.; Zheng, X.; Mao, X.; Wang, L.; Xiong, H. (Shanghai); Herth, F.J.F. (Heidelberg); Han, B. (Shanghai)

339 Optoelectronic Plethysmography in Clinical Practice and Research: A Review
Massaroni, C. (Rome); Carraro, E. (Concegiano); Vianello, A. (Padova); Miccinilli, S.; Morrone, M. (Rome); Levai, I.K. (Chatham Maritimes); Schena, E.; Saccomandi, P.; Sterzi, S. (Rome); Dickinson, J.W.; Winter, S. (Chatham Maritime); Silvestri, S. (Rome)

355 Simulation-Based Training in Flexible Bronchoscopy and Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA): A Systematic Review
Naur, T.M.H.; Nilsson, P.M. (Copenhagen); Pietersen, P.I. (Odense); Clementsen, P.F. (Copenhagen/Roskilde); Konge, L. (Copenhagen)

363 Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Position Paper of the Swiss Working Group for Interstitial and Rare Lung Diseases of the Swiss Respiratory Society
Funke-Chambour, M. (Bern); Azzola, A. (Lugano); Adler, D.; Barazzone-Arrighoffo, C. (Geneva); Benden, C.; Boehler, A. (Zurich); Breivaux, P-O. (Sion); Brutsche, M. (St. Gallen); Clarembach, C.F. (Zurich); Hostettler, K. (Basel); Kleiner-Finger, R. (Sion); Nicod, L.P. (Lausanne); Soccal, P.M. (Geneva); Tamm, M. (Basel); Geiser, T. (Bern); Lazor, R. (Lausanne)